Suggested remit: To appraise the clinical and cost effectiveness of rucaparib within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
5100
|
Provisional Schedule
| Committee meeting: 1 |
11 June 2024 |
| Expected publication |
21 August 2024 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Liverpool Reviews and Implementation Group, University of Liverpool |
Stakeholders
| Companies sponsors |
Pharma& |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Ovacome |
| |
Ovarian Cancer Action |
| |
Target Ovarian Cancer |
| Professional groups |
Association of Cancer Physicians |
| |
British Gynaecological Cancer Society |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Comparator companies |
AstraZeneca |
| |
Pfizer |
| |
Roche Products |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
BNF |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
MHRA |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
30 October 2023
|
In progress. STA appraisal |
|
30 October 2023
|
Invitation to participate |
|
15 September 2023
|
Draft scope documents |
|
30 June 2023
|
Please note that following on from an update received from the company, appraisal has been scheduled into the work programme. The appraisal is now anticipated to begin during late October 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-January 2024. |
|
07 December 2022
|
Unfortunately, the company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
|
07 December 2022
|
Suspended. Unfortunately, the company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
|
26 October 2022 - 23 November 2022
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
26 October 2022
|
In progress. Scoping commenced |
|
30 March 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual